Skip to main content
. 2026 Sep 20;18(9):1046. doi: 10.3390/v18091046
3TC Lamivudine
ABC Abacavir
ANOVA Analysis of variance
ART Antiretroviral therapy
ARV Antiretroviral drug
AZT Zidovudine
d4T Lamivudine
ddI Didanosine
DMEM Dulbecco’s modified Eagle medium
DOR Doravirine
dNTP Deoxyribonucleotide triphosphate
FC Fold change
FTC Emtricitabine
HIV-1 Human immunodeficiency virus type-1
HEK Human embryonic kidney
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
IC50 Inhibitory concentration-50
ISL Islatravir
_Rev Reversion of M184V to M184)
LB Luria-Bertani
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTI Nucleos(t)ide reverse transcriptase inhibitor
NRTtI Nucleoside reverse transcriptase translocation inhibitor
PCR Polymerase chain reaction
PEImax Polyethylenimine-max
PLWH People living with HIV
RLU Relative light units
RT Reverse transcriptase
SD Standard deviation
SEM Standard error of the mean
SOB Super optimal broth
TAM2 Thymidine analogue mutation type 2
TCO Technical cutoff
TNF Tenofovir
VSV-G Vesicular stomatitis virus glycoprotein